Clinical application of DNA ploidy to cervical cancer screening: A review

World Journal of Clinical Oncology

Volumn 5, Issue 5, 2014, Pages 931-965

  Garner, David ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Automated quantitative image cytometry; Cervical cancer screening; DNA ploidy; High risk HPV testing

Indexed keywords

EID: 84929413365     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i5.931     Document Type: Article

References (205)

1. Sun XR, Wang J, Garner D, Palcic B. Detection of cervical cancer and high grade neoplastic lesions by a combination of liquid-based sampling preparation and DNA measurements using automated image cytometry. Cell Oncol 2005; 27: 33-41 [PMID: 15750205]
2. Biesterfeld S, Gerres K, Fischer-Wein G, Böcking A. Polyploidy in non-neoplastic tissues. J Clin Pathol 1994; 47: 38-42 [PMID: 8132807]
3. Zasadil LM, Britigan EM, Weaver BA. 2n or not 2n: Aneuploidy, polyploidy and chromosomal instability in primary and tumor cells. Semin Cell Dev Biol 2013; 24: 370-379 [PMID: 23416057 DOI: 10.1016/j.semcdb.2013.02.001]
4. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol 2006; 18: 658-667 [PMID: 17046232 DOI: 10.1016/j.ceb.2006.10.002]
5. Hansemann D. Ueber asymmetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung. Virchows Arch 1890; 119: 299-326
6. Hansemann D. Ueber pathologische Mitosen. Virchows Arch 1891; 123: 356-370
7. Bignold LP, Coghlan BL, Jersmann HP. David Paul Hansemann: chromosomes and the origin of the cancerous features of tumor cells. Cell Oncol 2009; 31: 61 [PMID: 19096152 DOI: 10.3233/CLO-2009-0451]
8. Köhler A. Ein neues Beleuchtungsverfahren für mikrophotographische Zwecke. Zeitschrift für wissenschaftliche Mikroskopie und für Mikroskopische Technik [Internet] 1893; 10: 433-440. Available from: URL: http://www.archive.org/stream/zeitschriftfrw10stut#page/432/mode/2up
9. Boveri T. Über mehrpolige Mitosen als Mittel zur Analyse des Zellkerns. Verh Phys Med Gesellschaft Würzburg 1902; 35: 67-90
10. Boveri T. [On Multipolar Mitosis as a Means of Analysis of the Cell Nucleus] [Internet]. Available from: URL: http://10e.devbio.com/article.php?id=74
11. Boveri T. Zur Frage der Entstehung maligner Tumoren. Fischer Verlag: Jena, 1914
12. Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci 2008; 121 Suppl 1: 1-84 [PMID: 18089652 DOI: 10.1242/jcs.025742]
13. Boveri T. The origin of malignant tumors. Baltimore: Williams and Wilkins, 1929
14. Wunderlich V. JMM-past and present. Chromosomes and cancer: Theodor Boveri's predictions 100 years later. J Mol Med (Berl) 2002; 80: 545-548 [PMID: 12226736 DOI: 10.1007/s00109-002-0374-y]
15. Duijf PH, Schultz N, Benezra R. Cancer cells preferentially lose small chromosomes. Int J Cancer 2013; 132: 2316-2326 [PMID: 23124507 DOI: 10.1002/ijc.27924]
16. Krajcovic M, Overholtzer M. Mechanisms of ploidy increase in human cancers: a new role for cell cannibalism. Cancer Res 2012; 72: 1596-1601 [PMID: 22447569 DOI: 10.1158/0008-5472. CAN-11-3127]
17. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009; 460: 278-282 [PMID: 19506557 DOI: 10.1038/nature08136]
18. Weaver BA, Cleveland DW. The role of aneuploidy in promoting and suppressing tumors. J Cell Biol 2009; 185: 935-937 [PMID: 19528293 DOI: 10.1083/jcb.200905098]
19. Böcking A, Giroud F, Reith A. Consensus report of the ESACP task force on standardization of diagnostic DNA image cytometry. European Society for Analytical Cellular Pathology. Anal Cell Pathol 1995; 8: 67-74 [PMID: 7734413]
20. Haroske G, Baak JP, Danielsen H, Giroud F, Gschwendtner A, Oberholzer M, Reith A, Spieler P, Böcking A. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 2001; 23: 89-95 [PMID: 11904464]
21. Feulgen R, Rossenbeck H. Mikroskopisch-chemischer Nachweis einer Nucleinsaure vom Typus der Thymonucleinsaure und die darauf beruhende elektive Farbung von Zellkernen in mikroskopischen Praparaten. Z Physiol Chem 1924; 135: 203-248
22. Chieco P, Derenzini M. The Feulgen reaction 75 years on. Histochem Cell Biol 1999; 111: 345-358 [PMID: 10403113]
23. Chieco P, Jonker A, De Boer BA, Ruijter JM, Van Noorden CJ. Image cytometry: protocols for 2D and 3D quantification in microscopic images. Prog Histochem Cytochem 2013; 47: 211-333 [PMID: 23146330 DOI: 10.1016/j.proghi.2012.09.001]
24. Lapidus SN. Founder, former President and CEO Cytyc Corp., personal communication
25. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Young N. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-2119 [PMID: 11966386]
26. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285: 1500-1505 [PMID: 11255427]
27. CAAHEP Accredited Cytotechnology Programs. American Society of Cytopathology [Internet]. Available from: URL: http://www.cytopathology.org/caahep-accreditedcytotechnology-programs/
28. NAIT. Cytotechnology [Internet]. Available from: URL: http://www.nait.ca/program-home-76613.htm
29. Anshu A, Cochand-Priollet B, Cross P, Desai M, Dina R, Duskova J, Evered A, Farnsworth A, Gray W, Gupta SS, Kapila K, Kardum-Skelin I, Kloboves-Prevodnik V, Kobayashi TK, Koutselini H, Olszewski W, Onal B, Pitman MB, Marinsek Z, Sauer T, Schenck U, Schmitt F, Shabalova I, Smith JH, Tani E, Vass L, Vielh P, Wiener H. Survey of medical training in cytopathology carried out by the journal Cytopathology. Cytopathology 2010; 21: 147-156 [PMID: 20482722 DOI: 10.1111/j.1365-2303.2010.00761.x]
30. Booklet of information 2013 [Internet]. Available from: URL: http://www.abpath.org/BookletofInformation.pdf
31. Specialty Training Requirements in Anatomical Pathology [Internet]. Available from: URL: http://www.royalcollege. ca/cs/groups/public/documents/document/y2vk/mdaw/~edisp/tztest3rcpsced000604.pdf
32. Competency Training Requirements for the Area of Focused Competence in Cytopathology [Internet]. Available from: URL: http://www.royalcollege.ca/cs/groups/public/documents/document/mdaw/mday/~edisp/002207.pdf
33. Davey DD, Cox JT, Austin RM, Birdsong G, Colgan TJ, Howell LP, Husain M, Darragh TM. Cervical cytology specimen adequacy: patient management guidelines and optimizing specimen collection. J Low Genit Tract Dis 2008; 12: 71-81 [PMID: 18369299 DOI: 10.1097/LGT.0b013e3181585b9b]
34. McQueen F, Duvall E. Using a quality control approach to define an 'adequately cellular' liquid-based cervical cytology specimen. Cytopathology 2006; 17: 168-174 [PMID: 16879263 DOI: 10.1111/j.1365-2303.2006.00344.x]
35. Bishop JW. Cellularity of liquid-based, thin-layer cervical cytology slides. Acta Cytol 2002; 46: 633-636 [PMID: 12146022]
36. Studeman KD, Ioffe OB, Puszkiewicz J, Sauvegeot J, Henry MR. Effect of cellularity on the sensitivity of detecting squamous lesions in liquid-based cervical cytology. Acta Cytol 2003; 47: 605-610 [PMID: 12920754]
37. Swift H. The constancy of desoxyribose nucleic acid in plant nuclei. Proc Natl Acad Sci USA 1950; 36: 643-654 [PMID: 14808154]
38. Ris H, Mirsky AE. Quantitative cytochemical determination of desoxyribonucleic acid with the Feulgen nucleal reaction. J Gen Physiol 1949; 33: 125-146 [PMID: 15392564]
39. Screening for Cancer of the Cervix-An Office Manual for Health Professionals [Internet]. 2013; Available from: URL: http://www.screeningbc.ca/NR/rdonlyres/21BBF070-6504-4A37-A1BB-45563BF387C7/63243/CCSPmanual-Mar2013-Small1.pdf
40. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL. Human papillomavirus DNA vs Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-1588 [PMID: 17942871 DOI: 10.1056/NEJMoa071430]
41. Guillaud M, Benedet JL, Cantor SB, Staerkel G, Follen M, MacAulay C. DNA ploidy compared with human papilloma virus testing (Hybrid Capture II) and conventional cervical cytology as a primary screening test for cervical high-grade lesions and cancer in 1555 patients with biopsy confirmation. Cancer 2006; 107: 309-318 [PMID: 1677 3634 DOI: 10.1002/cncr.21993]
42. Chatelain R, Schunck T, Schindler EM, Schindler AE, Böcking A. Diagnosis of prospective malignancy in koilocytic dysplasias of the cervix with DNA cytometry. J Reprod Med 1989; 34: 505-510 [PMID: 2810239]
43. Zhang Z, Liu Z. Clinical study of cellular DNA quantitative analysis method for cervical cancer screening. Xiandai Funv 2010; 9: 121-126
44. Bollmann R, Bankfalvi A, Griefingholt H, Trosic A, Speich N, Schmitt C, Bollmann M. Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening: results from 31031 women from the Bonn-region in West Germany. Oncol Rep 2005; 13: 915-922 [PMID: 15809758]
45. Li M, Liu F, Di Y, Deng Q, Zhong P. Value of DNA quantitative analysis combined with colposcopy for diagnosis of cervical cancer and high-grade cervical intraepithelial neoplasia. Zhongguo Fuyou Baojian 2012; 27: 2841-2844
46. Li G, Guillaud M, Follen M, MacAulay C. Double staining cytologic samples with quantitative Feulgen-thionin and anti-Ki-67 immunocytochemistry as a method of distinguishing cells with abnormal DNA content from normal cycling cells. Anal Quant Cytol Histol 2012; 34: 273-284 [PMID: 23301387]
47. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer 2009; 125: 2489-2496 [PMID: 19626591 DOI: 10.1002/ijc.24774]
48. Adriaensen WJ, Matheï C, Buntinx FJ, Arbyn M. A framework provided an outline toward the proper evaluation of potential screening strategies. J Clin Epidemiol 2013; 66: 639-647 [PMID: 23395357 DOI: 10.1016/j.jclinepi.2012.09.018]
49. van Hemel BM, Haarsma JG, Ruitenbeek T, Groen HJ, Suurmeijer AJ. Application of the ThinPrep imaging system in urine cytology: a prospective study. Cancer Cytopathol 2013; 121: 410-414 [PMID: 23907818 DOI: 10.1002/cncy.21301]
50. Cervical Cancer Screening Program 2012 Annual Report [Internet]. Available from: URL: http://www.screeningbc. ca/NR/rdonlyres/F2D89BB9-3B33-4DBD-BE76-975A220B0C7B/69596/CCSPAnnualReport2012Print-Version.pdf
51. Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007; 127: 335-337 [PMID: 17276947 DOI: 10.1309/RNF3C01JKADQCLKP]
52. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-520 [PMID: 18973271 DOI: 10.1002/ijc.24010]
53. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010; 134: 193-199 [PMID: 20660320 DOI: 10.1309/AJCPRI8XPQUEAA3K]
54. Screening Mammography Program 2013 Annual Report [Internet]. Available from: URL: http://www.screeningbc.ca/NR/rdonlyres/D302DDFE-474D-48F2-912D-F5612AA8B204/68074/SMPAnnualReport2013Rev14January2014.pdf
55. Tong H, Wang Z, Ming S, Yan K, Yan J, Li F. DNA ploidy analysis and routine cytologic diagnosis of cervical intraepithelial neoplasia compared diagnostic evaluation. Zhonghua Linchuang Yishi Zazhi (Dianzi Ban) 2009; 3: 47-55.
56. Lord SJ, Staub LP, Bossuyt PM, Irwig LM. Target practice: choosing target conditions for test accuracy studies that are relevant to clinical practice. BMJ 2011; 343: d4684 [PMID: 21903693 DOI: 10.1136/bmj.d4684]
57. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasiagrade 2. Obstet Gynecol 2009; 113: 18-25 [PMID: 19104355 DOI: 10.1097/AOG.0b013e31818f5008]
58. Wang SM, Colombara D, Shi JF, Zhao FH, Li J, Chen F, Chen W, Li SM, Zhang X, Pan QJ, Belinson JL, Smith JS, Qiao YL. Six-year regression and progression of cervical lesions of different human papillomavirus viral loads in varied histological diagnoses. Int J Gynecol Cancer 2013; 23: 716-723 [PMID: 23455757 DOI: 10.1097/IGC.0b013e318286a95d]
59. Sasieni P, Castanon A, Parkin DM. How many cervical cancers are prevented by treatment of screen-detected disease in young women? Int J Cancer 2009; 124: 461-464 [PMID: 18844220 DOI: 10.1002/ijc.23922]
60. Sasieni PD, Castanon A, Parkin MD. Response to: Why young women should be screened for cervical cancer: The distinction between CIN2 and CIN3. Int J Cancer 2009; 126: 2257-2258 [DOI: 10.1002/ijc.24785]
61. Morrison BJ, Coldman AJ, Boyes DA, Anderson GH. Forty years of repeated screening: the significance of carcinoma in situ. Br J Cancer 1996; 74: 814-819 [PMID: 8795587]
62. Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010; 116: 1373-1380 [PMID: 21099605 DOI: 10.1097/AOG.0b013e3181fe777f]
63. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, Miller S, Canjura-Clayton KL, Farhat S, Broering JM, Darragh TM. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364: 1678-1683 [PMID: 15530628 DOI: 10.1016/S0140-6736(04)17354-6]
64. Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, Mitsuhashi A, Fujii T, Hirai Y, Iwasaka T, Yaegashi N, Watanabe Y, Nagai Y, Kitagawa T, Yoshikawa H. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer 2011; 128: 2898-2910 [PMID: 20734388 DOI: 10.1002/ijc.25630]
65. Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol 2013; 178: 1161-1169 [PMID: 23897645 DOI: 10.1093/aje/kwt077]
66. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013; 17: S1-S27 [PMID: 23519301 DOI: 10.1097/LGT.0b013e318287d329]
67. Wuntakal R, Castanon A, Sasieni PD, Hollingworth A. Pregnancy outcomes after treatment for cervical intraepithelial neoplasia in a single NHS hospital. Int J Gynecol Cancer 2013; 23: 710-715 [PMID: 23446377 DOI: 10.1097/IGC.0b013e3182885496]
68. Castanon A, Brocklehurst P, Evans H, Peebles D, Singh N, Walker P, Patnick J, Sasieni P. Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospectiveprospective cohort study. BMJ 2012; 345: e5174 [PMID: 22899563 DOI: 10.1136/bmj.e5174]
69. Lima AF, Francisco C, Júlio C, Paula T, Vitorino A, Borrego J. Obstetric outcomes after treatment for cervical intraepithelial neoplasia: six years of experience. J Low Genit Tract Dis 2011; 15: 276-279 [PMID: 21959571 DOI: 10.1097/LGT.0b013e31821a6823]
70. Cotton S, Sharp L, Cochran C, Gray N, Cruickshank M, Smart L, Thornton A, Little J. After-effects reported by women having follow-up cervical cytology tests in primary care: a cohort study within the TOMBOLA trial. Br J Gen Pract 2011; 61: e333-e339 [PMID: 21801512 DOI: 10.3399/bjgp11X578007]
71. Sharp L, Cotton S, Cochran C, Gray N, Little J, Neal K, Cruickshank M. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG 2009; 116: 1506-1514 [PMID: 19583712 DOI: 10.1111/j.1471-0528.2009.02263.x]
72. Bevis KS, Biggio JR. Cervical conization and the risk of preterm delivery. Am J Obstet Gynecol 2011; 205: 19-27 [PMID: 21345402 DOI: 10.1016/j.ajog.2011.01.003]
73. Sasieni PD, Castanon A, Cuzick J. NHSCSP No 31: The impact of cervical screening on young women: A critical review of the literature [Internet]. Available from: URL: http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp31.html
74. Vesco K, Whitlock E, Eder M, Lin J. Screening for Cervical Cancer: A Systematic Evidence Review for the US Preventive Services Task Force [Internet]. Available from: URL: http://www.ncbi.nlm.nih.gov/books/NBK66099/
75. Kulasingam S, Havrilesky L, Ghebre R. Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force [Internet]. Available from: URL: http://www.ncbi.nlm.nih.gov/books/NBK92546/
76. Bao L. Clinical Observation on the Diagnosis of High-grade Cervical Intraepithelial Neoplasia and Cervical Cancer using Automatic DNA Ploidy Analysis. Zhongguo Jihua Shengyuxue Zazhi 2009; 163: 292-294.
77. Xue X, Kim MY, Castle PE, Strickler HD. A new method to address verification bias in studies of clinical screening tests: cervical cancer screening assays as an example. J Clin Epidemiol 2014; 67: 343-353 [PMID: 24332397 DOI: 10.1016/j.jclinepi.2013.09.013]
78. Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K, Peacock SJ, Smith LW, Kan L, Cook DA, Mei W, Stuart GC, Franco EL, Coldman AJ. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer 2010; 10: 111 [PMID: 20334685 DOI: 10.1186/1471-2407-10-111]
79. Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, Sellors JW, Franceschi S, Qiao YL, Castle PE. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010; 11: 1160-1171 [PMID: 21075054 DOI: 10.1016/S1470-2045(10)70256-4]
80. Schatzkin A, Connor RJ, Taylor PR, Bunnag B. Comparing new and old screening tests when a reference procedure cannot be performed on all screenees. Example of automated cytometry for early detection of cervical cancer. Am J Epidemiol 1987; 125: 672-678 [PMID: 3826045]
81. Chock C, Irwig L, Berry G, Glasziou P. Comparing dichotomous screening tests when individuals negative on both tests are not verified. J Clin Epidemiol 1997; 50: 1211-1217 [PMID: 9393377 DOI: 10.1016/S0895-4356(97)00122-4]
82. Tian YW, Liu G, Zhou J, Gao L, Zhu CY. Application of DNA image cytometry in the cervical intraepithelial neoplasia and cervical cancer screening. Zhenduan Binglixue Zazhi 2013; 20: 425-428
83. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health technology assessment (Winchester, England) 2007; 11: iii-ix-51
84. Stock EM, Stamey JD, Sankaranarayanan R, Young DM, Muwonge R, Arbyn M. Estimation of disease prevalence, true positive rate, and false positive rate of two screening tests when disease verification is applied on only screenpositives: a hierarchical model using multi-center data. Cancer Epidemiol 2012; 36: 153-160 [PMID: 21856264 DOI: 10.1016/j.canep.2011.07.001]
85. de Groot JA, Bossuyt PM, Reitsma JB, Rutjes AW, Dendukuri N, Janssen KJ, Moons KG. Verification problems in diagnostic accuracy studies: consequences and solutions. BMJ 2011; 343: d4770 [PMID: 21810869 DOI: 10.1136/bmj.d4770]
86. Alonzo TA. Verification bias-corrected estimators of the relative true and false positive rates of two binary screening tests. Stat Med 2005; 24: 403-417 [PMID: 15543634 DOI: 10.1002/sim.1959]
87. Fluss R, Reiser B, Faraggi D, Rotnitzky A. Estimation of the ROC curve under verification bias. Biom J 2009; 51: 475-490 [PMID: 19588455 DOI: 10.1002/bimj.200800128]
88. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, Qiao YL. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004; 191: 430-434 [PMID: 15343217 DOI: 10.1016/j.ajog.2004.02.065]
89. Ferris DG, Litaker MS. Prediction of cervical histologic results using an abbreviated Reid Colposcopic Index during ALTS. Am J Obstet Gynecol 2006; 194: 704-710 [PMID: 16522401 DOI: 10.1016/j.ajog.2005.10.204]
90. Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, Schiffman M, Solomon D, Jeronimo J. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006; 108: 264-272 [PMID: 16880294 DOI: 10.1097/01. AOG.0000220505.18525.85]
91. Hearp ML, Locante AM, Ben-Rubin M, Dietrich R, David O. Validity of sampling error as a cause of noncorrelation. Cancer 2007; 111: 275-279 [PMID: 17665495 DOI: 10.1002/cncr.22945]
92. Moss EL, Moran A, Douce G, Parkes J, Todd RW, Redman CW. Cervical cytology/histology discrepancy: a 4-year review of patient outcome. Cytopathology 2010; 21: 389-394 [PMID: 20482721 DOI: 10.1111/j.1365-2303.2010.00754.x]
93. Pretorius RG, Kim RJ, Belinson JL, Elson P, Qiao YL. Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis 2006; 10: 5-9 [PMID: 16378026]
94. Cagle AJ, Hu SY, Sellors JW, Bao YP, Lim JM, Li SM, Lewis K, Song Y, Ma JF, Pan QJ, Zhang WH, Zhao FH, Qiao YL. Use of an expanded gold standard to estimate the accuracy of colposcopy and visual inspection with acetic acid. Int J Cancer 2010; 126: 156-161 [PMID: 19585573 DOI: 10.1002/ijc.24719]
95. Pretorius RG, Bao YP, Belinson JL, Burchette RJ, Smith JS, Qiao YL. Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer 2007; 121: 2218-2224 [PMID: 17657715 DOI: 10.1002/ijc.22991]
96. Phelps CE, Hutson A. Estimating diagnostic test accuracy using a "fuzzy gold standard". Med Decis Making 1995; 15: 44-57 [PMID: 7898298]
97. Pretorius RG, Belinson JL, Azizi F, Peterson PC, Belinson S. Utility of random cervical biopsy and endocervical curettage in a low-risk population. J Low Genit Tract Dis 2012; 16: 333-338 [PMID: 22622343 DOI: 10.1097/LGT.0b013e3182480c18]
98. Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, Joura EA, Djursing H, Sigurdsson K, Jefferson L, Alvarez F, Sings HL, Lu S, James MK, Saah A, Haupt RM. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer 2011; 128: 1354-1362 [PMID: 20506504 DOI: 10.1002/ijc.25470]
99. Pretorius RG, Belinson JL, Burchette RJ, Hu S, Zhang X, Qiao YL. Regardless of skill, performing more biopsies increases the sensitivity of colposcopy. J Low Genit Tract Dis 2011; 15: 180-188 [PMID: 21436729 DOI: 10.1097/LGT.0b013e3181fb4547]
100. Labeling Digene HC2 Suppl 9 P890064S009c [Internet]. Available from: URL: http://www.accessdata.fda.gov/cdrh-docs/pdf/P890064S009c.pdf
101. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1462-1470 [PMID: 17895475 DOI: 10.1093/jnci/djm150]
102. Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, Bouchot O, Beurton D, Coulange C, Rambeaud JJ. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003; 169: 921-924 [PMID: 12576813 DOI: 10.1097/01. ju.0000048983.83079.4c]
103. Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-890 [PMID: 21865084 DOI: 10.1016/S1470-2045(11)70188-7]
104. Hayen A, Macaskill P, Irwig L, Bossuyt P. Appropriate statistical methods are required to assess diagnostic tests for replacement, add-on, and triage. J Clin Epidemiol 2010; 63: 883-891 [PMID: 20079607 DOI: 10.1016/j.jclinepi.2009.08.024]
105. Sedgwick P. Screening tests and indices of performance: effects of prevalence. BMJ 2011; 343: d6483 [DOI: 10.1136/bmj. d6483]
106. Cantor SB, Cárdenas-Turanzas M, Cox DD, Atkinson EN, Nogueras-Gonzalez GM, Beck JR, Follen M, Benedet JL. Accuracy of colposcopy in the diagnostic setting compared with the screening setting. Obstet Gynecol 2008; 111: 7-14 [PMID: 18165387 DOI: 10.1097/01.AOG.0000295870.677 52. b4]
107. Cárdenas-Turanzas M, Nogueras-Gonzalez GM, Scheurer ME, Adler-Storthz K, Benedet JL, Beck JR, Follen M, Cantor SB. The performance of human papillomavirus highrisk DNA testing in the screening and diagnostic settings. Cancer Epidemiol Biomarkers Prev 2008; 17: 2865-2871 [PMID: 18843032 DOI: 10.1158/1055-9965.EPI-08-0137]
108. Cárdenas-Turanzas M, Follen M, Nogueras-Gonzalez GM, Benedet JL, Beck JR, Cantor SB. The accuracy of the Papanicolaou smear in the screening and diagnostic settings. J Low Genit Tract Dis 2008; 12: 269-275 [PMID: 18820540 DOI: 10.1097/LGT.0b013e31816b44bc]
109. Leeflang MM, Rutjes AW, Reitsma JB, Hooft L, Bossuyt PM. Variation of a test's sensitivity and specificity with disease prevalence. CMAJ 2013; 185: E537-E544 [PMID: 23798453 DOI: 10.1503/cmaj.121286]
110. Liu GZ, Yang Q, Guang SF. The clinical value of DNA ploidy pattern analysis in screening for cervical cancer. Anhui Weisheng Zhiye Jishu Xueyuan Xuebao 2013; 12: 82-83
111. Xu S, Mei JH, Han YL, Wang SS, Xiong YF. Quantitative analysis of cervical cell DNA and liquid-based cytology in cervical screening of early lesions Comparison. Guangdong Yixue 2013; 34: 1387-1390
112. Chen CY, Yi WJ. Liquid-based cervical cytology TBS combined quantitative analysis of cervical cell DNA in cervical cancer screening examination application value. Guangxi Yixue 2013; 35: 594-596
113. Zhang XH. Quantitative analysis of DNA ploidy advantage in the ultra-early stage cervical cancer screening. Jilin Yixue 2013; 34: 2679-2680
114. Kang YQ, OuYang XH, He D, Jiang P, Yan ZX. Super early screening of cervical cell DNA Clinical analysis of cervical lesions. Zhongguo Yixue Chuangxin 2013; 10: 134-135 [DOI: 10.3969/j.issn.1674-4985.2013.09.072]
115. Ceng Y, Zuo J, Ceng Y, Sun X, Li Z. Quantitative detection of DNA in cervical cancer screening. Guoji Jianyan Yixue Zazhi 2013; 34: 199-200-219 [DOI: 10.3969/j.is]
116. Wang G, Li W, Shi S, Cao Y, Tang T. Clinical Applications of DNA Ploidy Analysis in Screening Cervical Carcinoma. Zhongguo Zhongliu Linchuang 2012; 21: 1639-1642
117. Sun X. DNA Image Cytometry in Cervical Squamous Lesions. JASC 2012; 1: S31
118. Hou A, Zhang Y, Ly X, Shao X, Wang X. A evaluation on cervical intraepithelial lesion and cervical cancer screening by DNA quantitative analysis and liquid-based monolayer cytology. Zhongguo Shiyan Zhenduanxue 2012; 4: 653-655
119. Wei LF, Lin HM, Qin YAF. Clinical research of cervical cell DNA quantitative analysis in opportunistic screening of cervical diseases among women in cities of Zhuang national minority regions. Huaxia Yixue 2012; 25: 181-184
120. Zhang YB. Quantitative analysis of DNA and liquid-based cytology in cervical lesion screening clinical observation. Guangxi Yike Daxue Xuebao 2012; (2): 253-255
121. Lan M, Cheng X, Zhu C, Liu T. Value of automatic DNA image cytometry in cervical intraepithelial neoplasia and cervical cancer screening. Zhenduan Binglixue Zazhi 2012; 19: 15-18
122. Jia Y. Application of quantitative analysis of DNA ploidy combined HR-HPV screening for cervical cancer detection. Hebei Lianhe Daxue Xuebao (Yixueban) 2012; 14: 18-19
123. Hu Y. Quantitative analysis of DNA ploidy screening for cervical cancer detection technology feasibility and precancerous lesions in disease screening women. Yixue Xinxi. 2011; 24: 3582-3583
124. Qin Z. Quantitative analysis of DNA TBS reporting methods combined clinical analysis of cervical cancer screening. Weisheng Zhiye Jiaoyu 2011; 29: 144-145
125. Zhong P, Li M. The clinical significance of quantitative analysis of cervical cellular DNA in cervical cancer screening. Zhongguo Yiyao Daobao 2011; 8: 75-78
126. Yu XR, Liu Y, Wang X, Kuang QL, Li XF, Kuang CY, Li XR, Liu Y, Wang CY, Zhu CY. Cell quantitative analysis of DNA ploidy in cervical cancer screening. Zhenduan Binglixue Zazhi 2011; 18: 289-292
127. Shen N, Wang Q, He Z, Liu M, Xu T, Chen DM, Zhang H, Li P, Huang L, Guan YX, Jiang JY. The Study of Application of DNA Image Cytometry in Cervical Cancer Screening and Analysis on the Misunderstanding. Zhongguo Xiandai Yisheng 2011; 49: 75-76
128. Yao J. Screening for cervical cancer in women in Kaifeng City. Linchuang Yixue 2011; 31: 77-78
129. Chang K. Cervical TBS DNA quantitative cytology in cervical cancer screening cervical biopsy combined with the application. Zhongguo Fuyou Baojian 2011; 26: 5854-5855
130. Mei H, Wei X, Fang Y. Quantitative analysis of DNA for early screening of cervical cancer and precancerous lesions of clinical observation. Dangdai Yixue 2010; 16: 2-3 [DOI: 10.3969/j.issn.1009-4393.2010.15.002]
131. Huang H, Huang W, Huang Y. Application of DNA ploidy analysis of cervical screening. Jianyan Yixue Yu Linchuang 2010; 7: 724-725
132. Li Z, Zhang M, Li H. Improved Detection of Cervical Cancer and High Grade Neoplastic Lesions by a Combination of Conventional Cytology and DNA Automated Image Cytometer. J Cancer Ther 2010; 1: 47-51 [DOI: 10.4236/jct.2010.12008]
133. Tong H, Shen R, Wang Z, Kan Y, Wang Y, Li F, Wang F, Yang J, Guo X. DNA ploidy cytometry testing for cervical cancer screening in China (DNACIC Trial): a prospective randomized, controlled trial. Clin Cancer Res 2009; 15: 6438-6445 [PMID: 19825960 DOI: 10.1158/1078-0432. CCR-09-1689]
134. Liang Y, Huang W, Huang Y, Wei F, Qu D. The clinical significance of DNA quantitative analysis method for cervical cancer screening. Yixue Xinxi 2009; 1: 219-220
135. Li LJ, Wang K, Yang F, Cao Y. Clinic studies of carrying out cervical cancer general investigation using cell DNA quantitative analysis. Zhongguo Fuyou Baojian 2008; 23: 2319-2320
136. Ye X, Xiao J, Zhao X. DNA ploidy analysis in the application of early screening of cervical lesions. Shiyong Zhenduan yu Zhiliao Zazhi 2006; 20: 370-371
137. Sun X, Li Y, Che D, Yan X, Ling H, Hong Z. Cervical cancer screening by using DNA quantitative cytology. Zhenduan Binglixue Zazhi 2005; 12: 12-16
138. Yang Y, Zhang F, Zeng L, Rao J, Zhong M, Tu Z. Retrospective study on application of DNA image cytometer in the cervical cancer screening. Zhongguo Fuyou Baojian 2013; 28: 2304-2306
139. Liu J, Xie J, Chang Z, Ping J, Wang C, Wang J. Diagnostic significance of TCT combined with DNA quantitative analysis in cervical lesions screening of zhuang nationality in Guangxi province TCT. Jiepou Kexue Jinzhan 2012; 18: 269-271
140. Li M, Liu F, Zhong P. Quantitative analysis of DNA in cervical cancer and high-grade cervical intraepithelial neoplasia diagnosis. Guangdong Yixueyuan Xuebao 2011; 29: 153-155 [DOI: 10.3969/j.issn.1005-4057.2011.02.014]
141. Kan YJ, Shen Y, Tong H, Hua Q. Diagnostic Value of DNA Ploid Analysis for Cervical Lesions. Jilin Yixue 2011; 32: 430-432
142. Tu Q, Wang J, Che D, Tu H, Sun X. Determination of significance of aneuploid cells in cervical intraepithelial neoplasia grade. Linchuang Yu Shiyan Binglixue Zazhi 2007; 23: 235-236
143. Canadian Cancer Statistics [Internet]. Available from: URL:http://www.cancer.ca/~/media/cancer.ca/CW/cancer information/cancer101/Canadiancancerstatistics/canadiancancer-statistics-2013-EN.pdf
144. Complete Prevalence Cervical Cancer USA [Internet]. Available from: URL: http://seer.cancer.gov/faststats/selections.php?run=runit&output=3&data=5&statistic=9&race=1&sex=3&age=1&series=cancer&cancer=57
145. Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer 2012; 130: 641-652 [PMID: 21387308 DOI: 10.1002/ijc.26042]
146. Lei T, Mao WM, Lei TH, Dai LQ, Fang L, Chen WQ, Zhang SW. Incidence and mortality trend of cervical cancer in 11 cancer registries of China. Chin J Cancer Res 2011; 23: 10-14 [PMID: 23467450 DOI: 10.1007/s11670-011-0010-x]
147. Zhao FH, Hu SY, Zhang SW, Chen WQ, Qiao YL. Cervical cancer mortality in 2004-2005 and changes during last 30 years in China. Zhonghua Yufang Yixue Zazhi 2010; 44: 408-412
148. Lei T, Mao WM, Yang HJ, Chen XZ, Lei TH, Wang X. Study on cancer incidence through the Cancer Registry Program in 11 Cities and Counties, China. Zhonghua Liuxingbingxue Zazhi 2009; 30: 1165-1170
149. Chen JG, Zhu J, Parkin DM, Zhang YH, Lu JH, Zhu YR, Chen TY. Trends in the incidence of cancer in Qidong, China, 1978-2002. Int J Cancer 2006; 119: 1447-1454 [PMID: 16596645 DOI: 10.1002/ijc.21952]
150. Li J, Kang LN, Qiao YL. Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev 2011; 12: 1149-1153 [PMID: 21875257]
151. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-2686 [PMID: 21471563 DOI: 10.1093/annonc/mdr015]
152. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005; 14: 243-250 [PMID: 15668501]
153. Zhang R, Velicer C, Chen W, Liaw KL, Wu EQ, Liu B, Cui JF, Belinson JL, Zhang X, Shen GH, Chen F, Qiao YL. Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grades 1 or worse among 4215 Chinese women in a population-based study. Cancer Epidemiol 2013; 37: 939-945 [PMID: 24210584 DOI: 10.1016/j.canep.2013.10.005]
154. Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, Wu RF, Li CQ, Wei LH, Xu AD, Zhang WH, Pan QJ, Zhang X, Belinson JL, Sellors JW, Smith JS, Qiao YL, Franceschi S. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer 2012; 131: 2929-2938 [PMID: 22488743 DOI: 10.1002/ijc.27571]
155. Wu EQ, Liu B, Cui JF, Chen W, Wang JB, Lu L, Niyazi M, Zhao C, Ren SD, Li CQ, Gong XZ, Smith JS, Belinson JL, Liaw KL, Velicer C, Qiao YL. Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study. Cancer Causes Control 2013; 24: 795-803 [PMID: 23397310 DOI: 10.1007/s10552-013-0162-8]
156. Liu SS, Chan KY, Leung RC, Chan KK, Tam KF, Luk MH, Lo SS, Fong DY, Cheung AN, Lin ZQ, Ngan HY. Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women-a population-based study. PLoS One 2011; 6: e19244 [PMID: 21559276 DOI: 10.1371/journal. pone.0019244]
157. Meng RL, Ma WJ, Xu YJ, Sond XL, Nie SP, Xu HF, Xu XJ, Cai QM, Xia Le. Screening rates of cervical cancer, breast cancer and their influential factors in Guangdong Province. Huanan Yufang Yixue 2010; 36: 8-14
158. Health DO. Topical Health Report No. 4 Prevention and Screening of Cervical Cancer [Internet]. Available from: URL: http://www.chp.gov.hk/files/pdf/grp-thr-report4-en-20041209.pdf
159. Cervical Screening Programme-Statistics & Reports-Hong Kong [Internet]. Available from: URL: http://www.cervicalscreening. gov.hk/english/sr/sr-statistics-cc.html
160. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011; 12: 663-672 [PMID: 21684207 DOI: 10.1016/S1470-2045(11)70145-0]
161. Pan QJ, Hu SY, Zhang X, Ci PW, Zhang WH, Guo HQ, Cao J, Zhao FH, Lytwyn A, Qiao YL. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China. Cancer Cytopathol 2013; 121: 473-482 [PMID: 23907807 DOI: 10.1002/cncy.21297]
162. Motic Regulatory [Internet]. Available from: URL: http://www.med.motic.com/Page.aspx?PageCategoryId=7&Page ContentId=4&LangCode=zhcn
163. Landing Med Regulatory [Internet]. Available from: URL: http://landingmed.com/cn/
164. Garner DM, Guillaud MD, MacAulay CE. DNA ploidy cytometry testing for cervical cancer screening in China-letter. Clin Cancer Res 2010; 16: 3517; author reply 3517-3519 [PMID: 20570931 DOI: 10.1158/1078-0432.CCR-10-1058]
165. Tong H, Shen R, Kan Y, Wang Z, Wang Y, Li F. DNA Cytometry Testing for Cervical Cancer Screening-Response. Clin Cancer Res 2010; 16: 3517-3519 [DOI: 10.1158/1078-0432. CCR-10-1081]
166. LANDING MED [Internet]. Available from: URL: http://landingmed.com/wp-content/uploads/2013/04/cytoptic.pdf
167. The ThinPrep Pap Test: The Benefits of Dual Review Screening [Internet]. Available from: URL: http://www.thinprep.com/hcp/imaging-system/benefits-dual-review.html
168. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346-355 [PMID: 17904957 DOI: 10.1016/j.ajog.2007.07.047]
169. Zhang DL, Yang Y, Zhou LM. Significance of DNA ploidy analysis in diagnosis of ASCUS. Zhonghua Fuchanke Zazhi 2012; 47: 259-262 [PMID: 22781111 DOI: 10.3760/cma. j.issn.0529-567x.2012.04.005]
170. Yang Y, Wu X, Zhang D. Significance of DNA Quantitative Cytology and High Risk HPV-DNA Test in ASCUS Triage Diagnosis. Zhongliu Fangzhi Yanjiu 2013; 40: 671-674
171. Lorenzato M, Caudroy S, Nou JM, Dalstein V, Joseph K, Bellefqih S, Durlach A, Thil C, Dez F, Bouttens D, Clavel C, Birembaut P. Contribution of DNA ploidy image cytometry to the management of ASC cervical lesions. Cancer 2008; 114: 263-269 [PMID: 18618504 DOI: 10.1002/cncr.23638]
172. Chen G, Xu Y, Li L, Yang L. Clinical application values of DNA ploidy analysis of cervical cells and Thinprep cytologic test combined with HPV detection for diagnosis of cervical precancerous lesion. Zhongguo Fuyou Baojian 2013; 28: 1179-1181
173. Jiao H, Ye Y, Zhang J, Li Y, Xia C. Functions of DNA ploidy analysis combined with high-risk human papillomavirus detection in screening of cervical cancer. Zhongguo Fuyou Baojian 2012; 25: 3399-3401
174. Feng S, Feng S. Investigation and analysis on HPV infection status of 1 026 women of child-bearing age. Zhongguo Fuyou Baojian 2011; 26: 1374-1377
175. China's free cancer tests to benefit more rural women-People's Daily Online [Internet]. Available from: URL: http://english.peopledaily.com.cn/90782/90880/8437954.html
176. Li ZF, Wang SM, Shi JF, Zhao FH, Ma JF, Qiao YL, Feng XX. Combined screening of cervical cancer, breast cancer and reproductive tract infections in rural China. Asian Pac J Cancer Prev 2012; 13: 3529-3533 [PMID: 22994789 DOI: 10.7314/APJCP.2012.13.7.3529]
177. Yu ZX. Preliminary Report on Screening for Cervical Cancer and Breast Cancer in Shaanxi Province. Zhongguo Zhongliu 2010; 19: 377-379
178. Dowling EC, Klabunde C, Patnick J, Ballard-Barbash R. Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen 2010; 17: 139-146 [PMID: 20956724 DOI: 10.1258/jms.2010.010033]
179. Leung GM, Lam TH, Thach TQ, Woo PP, Wong IO, Hedley AJ. Mass breast screening is highly inefficient. Hong Kong Med J 2007; 13: 332; author reply 332-333 [PMID: 17664541]
180. Wong IO, Tsang JW, Cowling BJ, Leung GM. Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women. Cancer 2012; 118: 4394-4403 [PMID: 22359352 DOI: 10.1002/cncr.27448]
181. Report of cancer expert working group on cancer prevention and screening [Internet]. Available from: URL: http://www.chp.gov.hk/files/pdf/grp-cancer-cewg-en-20050121.pdf
182. Cancer Experts Working Group. Cancer Expert Working Group On Cancer Prevention and Screening Recommendations on Breast Cancer Screening [Internet]. Available from: URL: http://www.chp.gov.hk/files/pdf/recommendation s-on-breast-cancer-screening-2010.pdf
183. Turic B. President and CEO, Perceptronix Medical Imaging Corp., personal communication
184. Cervical cytology practice guidelines [Internet]. Available from: URL: http://www.cytology.org.hk/Download/Final Draft2.pdf
185. Young NA, Moriarty AT, Walsh MK, Wang E, Wilbur DC. The potential for failure in gynecologic regulatory proficiency testing with current slide validation criteria: results from the College of American Pathologists Interlaboratory Comparison in Gynecologic Cytology Program. Arch Pathol Lab Med 2006; 130: 1114-1118 [PMID: 16879010]
186. Anand S, Fan VY, Zhang J, Zhang L, Ke Y, Dong Z, Chen LC. China's human resources for health: quantity, quality, and distribution. Lancet 2008; 372: 177 4-1781 [PMID: 18930528 DOI: 10.1016/S0140-6736(08)61363-X]
187. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013; 17: S28-S35 [PMID: 23519302 DOI: 10.1097/LGT.0b013e318285423c]
188. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years. J Low Genit Tract Dis 2013; 17: S64-S68 [PMID: 23519307 DOI: 10.1097/LGT.0b013e3182854399]
189. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. J Low Genit Tract Dis 2013; 17: S78-S84 [PMID: 23519309 DOI: 10.1097/LGT.0b013e31828543c5]
190. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. J Low Genit Tract Dis 2013; 17: S43-S49 [PMID: 23519304 DOI: 10.1097/LGT.0b013e3182854269]
191. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis 2013; 17: S56-S63 [PMID: 23519306 DOI: 10.1097/LGT.0b013e318285437b]
192. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. J Low Genit Tract Dis 2013; 17: S50-S55 [PMID: 23519305 DOI: 10.1097/LGT.0b013e3182854282]
193. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis 2013; 17: S36-S42 [PMID: 23519303 DOI: 10.1097/LGT.0b013e3182854253]
194. Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Kinney WK. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. J Low Genit Tract Dis 2013; 17: S69-S77 [PMID: 23519308 DOI: 10.1097/LGT.0b013e31828543b1]
195. QIAGEN Announces Commercial Launch of CareHPV Test in China [Internet]. Available from: URL: http://www.evaluategroup. com/Universal/View.aspx?type=Story&id=420248
196. Human papillomavirus vaccine support [Internet]. Available from: URL: http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccine-support/
197. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij WM, Snijders PJ, Meijer CJ. Evaluation of 14 triage strategies for HPV DNA-positive women in populationbased cervical screening. Int J Cancer 2012; 130: 602-610 [PMID: 21400507 DOI: 10.1002/ijc.26056]
198. Bray F, Carstensen B, Møller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, Weiderpass E. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005; 14: 2191-2199 [PMID: 16172231 DOI: 10.1158/1055-9965.EPI-05-0231]
199. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) 2012; 21: 1031-1037 [PMID: 22816437 DOI: 10.1089/jwh.2011.3385]
200. Lönnberg S, Nieminen P, Luostarinen T, Anttila A. Mortality audit of the Finnish cervical cancer screening program. Int J Cancer 2013; 132: 2134-2140 [PMID: 22987437 DOI: 10.1002/ijc.27844]
201. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-532 [PMID: 24192252 DOI: 10.1016/S0140-6736(13)62218-7]
202. Kinney W, Fetterman B, Cox JT, Lorey T, Flanagan T, Castle PE. Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol 2011; 121: 309-313 [PMID: 21276605 DOI: 10.1016/j.ygyno.2010.12.361]
203. Guillaud M, Benedet JL, Follen M, Crain BT, MacAulay C. Scan-and-treat methodology using Azure A fast stain as a cost-effective cervical cancer screening alternative to visual inspection with acetic acid. Gynecol Oncol 2007; 107: S256-S259 [PMID: 17825881 DOI: 10.1016/j.ygyno.2007.07.010]
204. Jiao H, Ye Y, Xia C. Application and comparison of two kinds of staining methods for measurement of nuclear DNA contents. Zhongguo Tishixue yu Tuxiang Fenxi 2007; 12: 180-184
205. Biesterfeld S, Beckers S, Del Carmen Villa Cadenas M, Schramm M. Feulgen staining remains the gold standard for precise DNA image cytometry. Anticancer Res 2011; 31: 53-58 [PMID: 21273580]